Brief: Takeda Announces Positive Topline Results From Pivotal Phase 2/3 Clinical Trial Of Tak-881 In Primary Immunodeficiency Disease (Pid)

Takeda Pharmaceutical

04/05/2026 13:04

May 4 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T:

TAKEDA ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 2/3 CLINICAL TRIAL OF TAK-881 IN PRIMARY IMMUNODEFICIENCY DISEASE (PID)

TAKEDA PHARMACEUTICAL CO LTD - TAK-881 SHOWS SAFETY, EFFICACY, AND TOLERABILITY COMPARABLE TO HYQVIA

TAKEDA PHARMACEUTICAL CO LTD - TO SUBMIT TAK-881 FOR REGULATORY APPROVAL IN U.S., EU, JAPAN IN FY2026

Source text: ID:nBw5NXSr3a

Further company coverage: 4502.T

 ((Reuters.Briefs@thomsonreuters.com;))